PFE 8-K Current Reports
PFIZER INC - 355 current reports
PFIZER INC 8-K Report, Executive Changes (Jun 18, 2026)
Pfizer Inc. (PFE) has filed an 8-K report announcing a significant leadership change within its finance department. Effective August 15, 2026, Chief Financial Officer Dave Denton will step down to pursue an opportunity in the consumer goods sector. The company has emphasized that Mr. Denton's departure is voluntary and not due to any disagreements or concerns regarding Pfizer's financial performance, operations, or accounting practices. In light of Mr. Denton's departure, Pfizer has appointed Cecile Guegan, currently Senior Vice President of Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer, effective August 16, 2026. Ms. Guegan, a long-standing Pfizer employee since 2005 with extensive experience in various finance leadership roles within the company, will oversee the CFO responsibilities while a thorough search for a permanent successor is conducted. This transition is a key event for investors to monitor as it may impact financial strategy and investor relations.
PFIZER INC 8-K Report, Regulation FD Disclosure (Jun 18, 2026)
Pfizer Inc. (PFE) filed an 8-K on June 18, 2026, primarily to reaffirm its previously issued fiscal year 2026 financial guidance following the announcement of a Chief Financial Officer transition. The company reiterated its revenue guidance of $59.5 billion to $62.5 billion and its Adjusted Diluted Earnings Per Share (EPS) guidance of $2.80 to $3.00. This reaffirmation suggests that despite the executive change, Pfizer's management remains confident in the company's operational and financial outlook for the remainder of the fiscal year. Investors should note that this filing does not introduce new financial targets but rather confirms existing ones, providing a degree of stability amidst organizational adjustments. The extensive risk factors included in the filing underscore the inherent volatility and uncertainties associated with the pharmaceutical industry.
PFIZER INC 8-K Report, Financial Results (May 5, 2026)
Pfizer Inc. (PFE) has filed a Form 8-K on May 5, 2026, to report its financial results for the first quarter of 2026. The filing primarily incorporates by reference a press release, dated the same day, which details the company's performance and financial condition for the period. Investors should refer to the furnished press release (Exhibit 99) for specific financial data, operational highlights, and management commentary regarding Q1 2026. The 8-K itself serves as notification of the release of this information and does not contain detailed financial statements or disclosures beyond referencing the press release. While this 8-K filing doesn't provide the detailed figures directly within its text, it signals that Pfizer has communicated its Q1 2026 earnings. The furnished press release is the critical document for investors seeking to understand revenue, profitability, segment performance, and any forward-looking guidance or significant business developments announced by Pfizer during the reporting period. The filing also notes the inclusion of an interactive data file for enhanced data accessibility.
PFIZER INC 8-K Report, Shareholder Vote Results (Apr 27, 2026)
Pfizer Inc. (PFE) held its Annual Meeting of Shareholders on April 23, 2026, with the key outcomes being the election of its Board of Directors and the ratification of its independent auditor. All nominated directors received a substantial majority of "For" votes, indicating strong shareholder confidence in the current leadership. Additionally, the selection of KPMG LLP as the independent registered public accounting firm for fiscal year 2026 was overwhelmingly approved. Shareholders also approved the amended Pfizer Inc. 2019 Stock Plan and, on an advisory basis, the compensation of the Named Executive Officers. However, a shareholder proposal to adopt an Independent Chair Policy was not approved, signaling that the majority of shareholders prefer the current board structure. These outcomes reflect a generally supportive shareholder base for Pfizer's governance and executive compensation practices.
PFIZER INC 8-K Report, Financial Results (Feb 3, 2026)
Pfizer Inc. (PFE) has filed an 8-K report on February 3, 2026, to announce its financial results for the fourth quarter of 2025. The report primarily references a press release, filed as Exhibit 99, which contains the detailed financial performance for the quarter. Investors should refer to this press release for comprehensive information regarding Pfizer's operational and financial condition as of the end of 2025. This filing serves as a notification of the release of Q4 2025 earnings and is crucial for understanding the company's recent performance. While the 8-K itself is brief, it directs stakeholders to the accompanying press release for substantive details on revenue, profitability, and any forward-looking statements or guidance provided by the company. Investors are advised to consult Exhibit 99 for a complete picture of Pfizer's financial standing and its outlook.
PFIZER INC 8-K Report, Regulation FD Disclosure (Dec 16, 2025)
Pfizer Inc. (PFE) has filed an 8-K report detailing updated financial guidance. The company announced revised full-year 2025 revenue guidance and provided its full-year 2026 guidance, while reaffirming all other components of its 2025 financial outlook. This update is being communicated to investors via a press release filed as an exhibit to this report. Investors should pay close attention to the specifics of the revenue revision for 2025 and the outlook for 2026 as provided in the accompanying press release. While other 2025 guidance components remain unchanged, the revenue adjustments could signal shifts in market dynamics or product performance. The 2026 guidance will offer a forward-looking perspective on Pfizer's expected financial trajectory.
PFIZER INC 8-K Report, Corporate Update (Nov 21, 2025)
Pfizer Inc. (PFE) announced the successful completion of a significant public offering of various debt securities on November 21, 2025. The offering comprised an aggregate principal amount of $6.75 billion across multiple tranches, including Floating Rate Notes due 2027 and fixed-rate notes maturing between 2027 and 2065 with coupon rates ranging from 3.875% to 5.700%. This substantial capital raise was executed under Pfizer's existing shelf registration statement. This offering indicates Pfizer's proactive approach to managing its capital structure and potentially funding ongoing operations, research and development, or strategic initiatives. The diverse maturity dates and interest rate structures of the notes suggest a strategy to diversify its debt profile and optimize borrowing costs. Investors should note the total size of the issuance and the specific terms of each note series to understand Pfizer's current debt obligations and its financial strategy.
PFIZER INC 8-K Report, Corporate Update (Nov 13, 2025)
Pfizer Inc. announced the successful completion of its acquisition of Metsera, Inc. for an enterprise value of approximately $7.0 billion. This strategic move signifies Pfizer's expansion into the obesity and metabolic disease market, a key growth area. The acquisition was executed through a merger agreement, with Metsera shareholders receiving $65.60 in cash per share at closing. In addition to the upfront cash payment, Metsera shareholders are eligible to receive contingent value rights (CVRs) worth up to an additional $20.65 per share. These CVRs are tied to the achievement of specific developmental and regulatory milestones related to Metsera's pipeline, notably its GLP-1 receptor antagonist and amylin analog drug candidates. Investors should closely monitor the progress of MET-097i and MET-233i, as their successful advancement could represent significant future value creation for Pfizer.
PFIZER INC 8-K Report, Financial Results (Nov 4, 2025)
Pfizer Inc. (PFE) has filed a Form 8-K on November 4, 2025, to report its financial results for the third quarter of 2025. The key information is contained within the press release furnished as Exhibit 99, which details the company's operational and financial performance for the period. Investors should refer to this press release for specific figures regarding revenue, earnings, and any forward-looking guidance provided by the company. While the 8-K itself is a procedural filing, the accompanying press release is the critical document for understanding Pfizer's recent financial health and outlook. The filing notes that the information furnished is not deemed "filed" for Section 18 purposes, but it is incorporated by reference into the press release, making it the primary source for investor analysis. Investors are encouraged to review the full press release for a comprehensive understanding of Pfizer's third-quarter 2025 performance.
PFIZER INC 8-K Report, Financial Results (Aug 5, 2025)
Pfizer Inc. (PFE) has filed a Current Report on Form 8-K to disclose its financial results for the second quarter of 2025, as announced in a press release dated August 5, 2025. While the filing itself is brief, it incorporates the full details of the second quarter performance via the furnished press release (Exhibit 99). Investors should refer to this press release for a comprehensive understanding of Pfizer's financial condition and operational results during the period. The company is providing this update on its financial performance, which is a critical disclosure for stakeholders assessing the company's ongoing business trajectory and health.
PFIZER INC 8-K Report, Corporate Update (May 19, 2025)
Pfizer Inc. (PFE) announced through its wholly-owned Dutch subsidiary, Pfizer Netherlands International Finance B.V., the successful completion of a substantial public offering of senior unsecured notes. The offering, totaling €3.25 billion across four tranches with varying maturities and interest rates, was made under a previously established shelf registration statement. This debt issuance represents a strategic move by Pfizer to raise capital, likely for general corporate purposes, potential acquisitions, or to refinance existing debt. The fully and unconditionally guaranteed nature of the notes by Pfizer Inc. provides investors with direct recourse to the parent company, enhancing the security of their investment. Investors should note the specific coupon rates and maturity dates for each tranche of notes, which indicate the cost of borrowing for Pfizer over different time horizons.
PFIZER INC 8-K Report, Financial Results (Apr 29, 2025)
Pfizer Inc. (PFE) filed an 8-K on April 29, 2025, primarily announcing its first-quarter 2025 financial results via a press release (Exhibit 99). While the specific financial figures are detailed in the press release, the 8-K highlights a significant expansion of its cost realignment program. This program, which aims to reduce selling, information, and administrative expenses (SI&A) through digital enablement and process simplification, now targets an additional $1.2 billion in savings, bringing the total expected net savings from the program to approximately $5.7 billion by the end of 2027. The company also identified further opportunities within its research and development (R&D) organization to drive productivity and operational efficiencies, anticipating an additional $500 million in savings by the end of 2026, which will be reinvested in R&D programs. Investors should note that these expanded cost-saving initiatives involve substantial one-time costs. The company anticipates approximately $1.6 billion in one-time costs through 2027 to achieve the additional $1.2 billion in savings, and approximately $600 million in one-time costs through 2026 to achieve the $500 million R&D savings. These initiatives are driven by enhanced digital enablement, including automation and artificial intelligence (AI), and simplification of business processes. Pfizer reaffirms its commitment to delivering net cost savings of approximately $4.5 billion by the end of 2025, as previously planned.
PFIZER INC 8-K Report, Shareholder Vote Results (Apr 28, 2025)
Pfizer Inc. (PFE) filed an 8-K on April 27, 2025, detailing the outcomes of its Annual Meeting of Shareholders held on April 24, 2025. The primary focus of the filing is the shareholder votes on several key proposals. Importantly, all director nominees presented were elected to the Board of Directors, indicating continued shareholder confidence in the current leadership. Furthermore, shareholders ratified the selection of KPMG LLP as Pfizer's independent registered public accounting firm for the fiscal year 2025, a standard procedure that suggests no major concerns regarding the company's auditors.
PFIZER INC 8-K Report, Financial Results (Feb 4, 2025)
Pfizer Inc. (PFE) has filed an 8-K report on February 4, 2025, announcing its financial results for the fourth quarter and the full year of 2024. The report primarily serves to furnish a press release detailing these financial outcomes, which was issued on the same day. Investors should refer to the furnished press release (Exhibit 99) for specific details regarding revenue, earnings, and any forward-looking guidance provided by the company. While this 8-K does not contain new operational or financial disclosures beyond the press release, it signifies the official release of Pfizer's latest performance data. The company is providing this information to ensure timely and broad dissemination of its financial condition and results of operations to the public and the investment community.
PFIZER INC 8-K Report, Regulation FD Disclosure (Dec 17, 2024)
Pfizer Inc. (PFE) has filed a Form 8-K to disclose important forward-looking financial information to investors. The company issued a press release on December 17, 2024, which provides its financial guidance for the full year 2025 and reaffirms its financial guidance for the full year 2024. This proactive disclosure is designed to keep the market informed about the company's financial expectations and strategic outlook.
PFIZER INC 8-K Report, Financial Results (Oct 29, 2024)
Pfizer Inc. (PFE) has filed an 8-K report on October 29, 2024, to announce its financial results for the third quarter of 2024. The report primarily serves to furnish a press release detailing these results, which was issued on the same day. Investors should note that this filing is furnished, not filed, and therefore does not carry the same implications under Section 18 of the Exchange Act. The key financial performance indicators and strategic updates will be found within the press release itself, which is incorporated by reference into this filing.
PFIZER INC 8-K Report, Executive Changes (Oct 15, 2024)
Pfizer Inc. has announced the election of Mortimer J. Buckley to its Board of Directors, effective October 10, 2024. Mr. Buckley's appointment brings additional expertise to the board, and he has been assigned to serve on both the Governance & Sustainability Committee and the Audit Committee. This strategic addition aims to strengthen the oversight and governance functions of the company. Investors should note that Mr. Buckley will be compensated and indemnified according to Pfizer's standard policies for non-employee directors. While this is a governance-related update, it signals the board's ongoing commitment to robust oversight and strategic direction. The accompanying press release, filed as an exhibit, provides further details on Mr. Buckley's background and the rationale behind his appointment.
PFIZER INC 8-K Report, Financial Results (Jul 30, 2024)
Pfizer Inc. (PFE) filed an 8-K on July 29, 2024, to report its financial results for the second quarter of 2024. The press release announcing these results, dated July 30, 2024, is furnished as an exhibit to this filing. This report primarily serves to provide investors with the company's latest financial performance details, including revenue, earnings, and potentially other key operational metrics. Investors should refer to the furnished press release (Exhibit 99) for the specific financial figures and management commentary. The filing itself, as per standard practice for Item 2.02, does not deem the information as officially "filed" for certain sections of securities law but ensures public access to the latest quarterly earnings announcement. The inclusion of the cover page in XBRL format further enhances data accessibility and analysis for market participants.
PFIZER INC 8-K Report, Executive Changes (Jul 26, 2024)
Pfizer Inc. (PFE) has filed an 8-K report detailing modifications to its long-term incentive compensation plans, specifically Five-Year Total Shareholder Return Units (TSRUs) and Performance Share Awards (PSAs) granted in 2022 and 2023. These changes, approved by the Compensation Committee, aim to enhance employee retention and realign executive compensation with long-term shareholder value, particularly in light of market conditions and the need to recover stock price. The modifications primarily involve extending the performance and settlement periods for these awards by two years. For TSRUs, the settlement date will be pushed back to February 2029 (from 2027) for 2022 grants and February 2030 (from 2028) for 2023 grants. Vesting periods are also extended to the fifth anniversary of the grant date. For PSAs, the three-year performance period will be extended by two years, with performance measured over the final three years of this extended term. This means 2022 PSAs will vest and settle in 2027 (instead of 2025), and 2023 PSAs in 2028 (instead of 2026). The treatment of these awards in the event of an employee's death has also been updated to align with 2024 grant terms. These modifications will be offered through a tender offer (Modification Offer) to eligible employees, including named executive officers.
PFIZER INC 8-K Report, Executive Changes (Jul 10, 2024)
Pfizer Inc. (PFE) has announced a significant leadership transition within its Research & Development division. Dr. Mikael Dolsten, the Chief Scientific Officer and President of Pfizer Research & Development, is initiating a search for his successor after a commendable 15-year tenure. This development signals a potential shift in the strategic direction or operational focus of Pfizer's crucial R&D efforts. Dr. Dolsten is expected to remain with the company in his current capacity until a successor is identified and a smooth transition is facilitated, with a commitment to stay through at least February 28, 2025. Investors should closely monitor the selection process for Dr. Dolsten's replacement, as the new appointee will play a vital role in shaping Pfizer's future drug pipeline and innovation strategy. The company's ability to attract top talent for this critical role will be a key indicator of its ongoing commitment to scientific advancement and long-term growth.
PFIZER INC 8-K Report, Executive Changes (Jul 1, 2024)
Pfizer Inc. (PFE) announced a significant change in its Board of Directors with the election of Cyrus Taraporevala, effective June 27, 2024. Mr. Taraporevala's appointment brings new expertise to the Board, and he has also been appointed to serve on the Audit Committee and the Compensation Committee. These committees play crucial roles in financial oversight and executive compensation, respectively, suggesting a focus on strengthening these critical governance areas. Investors should note that Mr. Taraporevala will be compensated according to Pfizer's standard non-employee director arrangements and will receive an indemnification agreement, which is typical for board members.
PFIZER INC 8-K Report, Exit or Disposal Costs (May 22, 2024)
Pfizer Inc. has announced a multi-year program aimed at reducing its cost of goods sold (COGS), a significant initiative for improving operational efficiency and profitability. The first phase of this program, focusing on operational efficiencies, is projected to yield approximately $1.5 billion in savings by the end of 2027, with some benefits anticipated to materialize starting in 2025. This cost-reduction effort will require an estimated $1.7 billion in one-time costs, primarily for severance and implementation expenses. These charges are expected to be recognized in 2024, with the majority of the cash outlays occurring in 2025 and 2026. Investors should note that these figures are estimates and subject to various assumptions, with actual results potentially differing. The company also cautions that future phases or unforeseen events could lead to additional charges.
PFIZER INC 8-K Report, Financial Results (May 1, 2024)
Pfizer Inc. (PFE) filed an 8-K on May 1, 2024, to announce its first-quarter 2024 financial results, as detailed in a press release furnished as Exhibit 99. While the 8-K itself does not contain the detailed financial figures, it serves as the official notification that Pfizer has publicly disclosed its Q1 2024 performance. Investors should refer to the press release (Exhibit 99) for the specific revenue, earnings, and operational metrics. The filing is standard procedure for material financial announcements. The key takeaway for investors is that the Q1 2024 results are now available and have been communicated by the company. It's crucial for shareholders and potential investors to review the accompanying press release to understand Pfizer's performance, including any forward-looking guidance or commentary provided by management regarding the company's outlook.
PFIZER INC 8-K Report, Shareholder Vote Results (Apr 29, 2024)
Pfizer Inc. (PFE) filed an 8-K report detailing the outcomes of its Annual Meeting of Shareholders held on April 25, 2024. The report primarily focuses on shareholder voting results for various proposals, including the election of directors, ratification of its independent auditor, and advisory votes on executive compensation. All incumbent director nominees were overwhelmingly elected, indicating strong shareholder confidence in the current board's leadership and governance. The selection of KPMG LLP as the independent registered public accounting firm for fiscal year 2024 also received substantial approval. Furthermore, shareholders voted in favor of the Amended and Restated Pfizer Inc. 2019 Stock Plan and approved, on an advisory basis, the compensation of the company's Named Executive Officers, signaling general agreement with the company's incentive structures and remuneration policies.
PFIZER INC 8-K Report, Financial Results (Jan 30, 2024)
Pfizer Inc. (PFE) filed an 8-K on January 29, 2024, to furnish a press release detailing its fourth-quarter and full-year 2023 financial results, released on January 30, 2024. This filing serves as the primary communication channel for these key financial performance metrics. Investors should refer to the furnished press release (Exhibit 99) for detailed information on the company's operational and financial condition during the reported periods. While the 8-K itself does not contain the financial figures, it directs investors to the press release for comprehensive data. This includes revenue, earnings, and any forward-looking statements or guidance provided by the company. The filing reiterates that the information furnished under Item 2.02 is not considered 'filed' for the purposes of Section 18 of the Exchange Act, meaning it does not carry the same legal implications as a formally filed document.
PFIZER INC 8-K Report, Corporate Update (Jan 10, 2024)
Pfizer Inc. (PFE) has filed an 8-K report on January 10, 2024, to disclose receipt of an unsolicited "mini-tender" offer from TRC Capital Investment Corporation. TRC Capital is attempting to purchase up to 4,000,000 shares of Pfizer common stock at $27.35 per share. This offer price is approximately 4.4% lower than Pfizer's closing stock price on December 27, 2023. The shares targeted represent a very small fraction (0.071%) of Pfizer's outstanding common stock. Crucially, Pfizer's management does not endorse this mini-tender offer and strongly recommends that its shareholders do not tender their shares. The company is not affiliated with TRC Capital or its offer. Shareholders who have already tendered their shares are advised they can withdraw them before the offer's expiration on January 30, 2024, or any extended date. Investors should exercise caution and consult Pfizer's official communications regarding this unsolicited offer.
PFIZER INC 8-K Report, Financial Results (Dec 14, 2023)
Pfizer Inc. (PFE) has announced the successful completion of its acquisition of Seagen Inc., a significant development for the company's oncology portfolio. The merger, effective December 14, 2023, involved Pfizer acquiring all outstanding shares of Seagen for $229.00 in cash per share. This transaction, originally agreed upon in March 2023, marks a major strategic move to bolster Pfizer's presence in the biotechnology and cancer treatment markets. The acquisition of Seagen brings a pipeline of innovative antibody-drug conjugate (ADC) technologies and late-stage cancer therapies into Pfizer's fold. Investors should view this as a strategic investment aimed at driving future growth, particularly in the high-demand area of oncology. While the immediate financial impact will be the cash outlay for the acquisition, the long-term value proposition lies in the potential of Seagen's assets to contribute to Pfizer's revenue and market leadership in cancer care.
PFIZER INC 8-K/A Report, Acquisition Completed (Dec 14, 2023)
Pfizer Inc. (PFE) has officially announced the completion of its acquisition of Seagen Inc. through a merger, effective December 14, 2023. This significant transaction involved Pfizer's wholly owned subsidiary, Aris Merger Sub, Inc., merging with and into Seagen, with Seagen now operating as a subsidiary of Pfizer. The acquisition details specify that each outstanding share of Seagen common stock was converted into a cash payment of $229.00 per share, subject to certain exceptions, and Seagen equity awards were also converted or adjusted accordingly.
PFIZER INC 8-K Report, Regulation FD Disclosure (Dec 13, 2023)
Pfizer Inc. (PFE) filed an 8-K on December 13, 2023, to furnish a press release issued on December 13, 2023, which provides its financial guidance for the full year 2024. This disclosure is crucial for investors seeking to understand the company's forward-looking financial outlook and strategic priorities for the upcoming fiscal year. The market will be closely watching these projections to assess Pfizer's expected performance, particularly in light of its ongoing business developments and the broader pharmaceutical landscape. While the 8-K itself does not contain detailed financial figures, it serves as the official channel through which Pfizer is communicating its 2024 guidance to the public. Investors should refer to the furnished press release (Exhibit 99.1) for the specific details of this guidance, which will likely encompass key metrics such as revenue, earnings per share, and potentially segment-specific performance, enabling a more informed investment decision.
PFIZER INC 8-K Report, Executive Changes (Dec 12, 2023)
Pfizer Inc. has announced significant organizational changes to its commercial operations, effective January 1, 2024, in anticipation of its acquisition of Seagen Inc. The company is establishing a dedicated Pfizer Oncology Division, which will consolidate oncology commercial and R&D functions from both Pfizer and Seagen. This new division will be led by Dr. Chris Boshoff, who will assume the role of Chief Oncology Officer. Concurrently, Pfizer's non-oncology commercial business will be divided into two distinct units: the Pfizer U.S. Commercial Division, led by Aamir Malik as Chief U.S. Commercial Officer, and the Pfizer International Commercial Division, headed by the newly appointed Alexandre de Germay as Chief International Commercial Officer. These structural shifts result in the elimination of the Chief Commercial Officer role currently held by Angela Hwang, who will transition to an Advisor to the CEO role and will receive severance and retirement benefits consistent with her existing entitlements. In parallel, Pfizer announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for the Seagen acquisition expired on December 11, 2023. With all necessary regulatory approvals now in hand, Pfizer expects to close the Seagen acquisition on December 14, 2023, subject to customary closing conditions.
PFIZER INC 8-K Report, Financial Results (Oct 31, 2023)
Pfizer Inc. (PFE) filed an 8-K on October 31, 2023, to report its financial results for the third quarter of 2023. The filing primarily incorporates by reference a press release issued on the same date, which contains the detailed financial outcomes for the period. Investors should refer to the press release (Exhibit 99) for specific figures regarding revenue, earnings, and other key financial metrics. While this 8-K itself does not provide the granular financial data, it formally announces the availability of Pfizer's Q3 2023 financial results. The furnishing of this information under Item 2.02 signifies that the company is disclosing material information to the public. Investors seeking a comprehensive understanding of Pfizer's performance in the third quarter will need to consult the referenced press release.
PFIZER INC 8-K Report, Financial Results (Oct 13, 2023)
Pfizer Inc. (PFE) has filed an 8-K report on October 13, 2023, to update investors on key financial and operational developments. The company announced an enterprise-wide cost realignment program aimed at achieving at least $3.5 billion in targeted savings. This program is expected to incur approximately $3.0 billion in one-time costs, with the majority being cash expenditures related to severance and implementation. The savings are anticipated to be realized with $1.0 billion in 2023 and $2.5 billion in 2024. Additionally, the filing references an updated press release that provides an update to Pfizer's previously issued guidance for the full year 2023. While specific guidance figures are not detailed in the 8-K text itself, this implies a revision to financial outlook for the current fiscal year. The report also mentions an amended supply agreement with the U.S. government for Paxlovid. Investors should monitor future filings and company communications for detailed financial results and the impact of these strategic initiatives.
PFIZER INC 8-K Report, Financial Results (Aug 1, 2023)
Pfizer Inc. (PFE) has filed an 8-K report on August 1, 2023, to announce its financial results for the second quarter ended July 31, 2023. The report primarily serves to furnish a press release detailing these results, which is incorporated by reference as Exhibit 99. Investors should note that this information, as is standard for Item 2.02 filings, is furnished and not deemed "filed" under the Securities Exchange Act of 1934, meaning it does not carry the same liability as formally filed information unless specifically incorporated into other filings. While the 8-K itself does not contain the detailed financial figures, it directs investors to the accompanying press release for the second quarter 2023 performance. This indicates that the key financial metrics, operational updates, and forward-looking statements are contained within that press release. Investors seeking a comprehensive understanding of Pfizer's performance for the reported period should consult Exhibit 99.
PFIZER INC 8-K Report, Executive Changes (Jul 27, 2023)
Pfizer Inc. announced a significant restructuring of its Research and Development (R&D) organization, strategically elevating Oncology to a standalone unit. This move is directly linked to Pfizer's planned future investments in oncology, including the proposed acquisition of Seagen Inc. The new structure aims to enhance focus and agility within its cancer drug development pipeline. As part of this reorganization, Dr. Mikael Dolsten, Chief Scientific Officer and President of Pfizer R&D, will oversee consolidated early and late-stage development, while Dr. Chris Boshoff transitions to Chief Oncology Research and Development Officer. Importantly, Dr. William Pao, the former Chief Development Officer, will be leaving the company effective August 15, 2023, due to the elimination of his role. His departure is classified as an involuntary termination without cause, triggering specific severance and equity acceleration provisions as outlined in his employment agreements and company plans.
PFIZER INC 8-K Report, Corporate Update (May 19, 2023)
Pfizer Inc. (PFE) has announced the completion of a substantial public offering totaling $30 billion in aggregate principal amount across eight different note issuances, ranging from 2025 to 2063 maturities and carrying interest rates between 4.450% and 5.340%. These notes are fully and unconditionally guaranteed by Pfizer Inc. on a senior unsecured basis. The primary purpose of this significant debt issuance is to finance a portion of the consideration for Pfizer's proposed acquisition of Seagen Inc. An important detail for investors is the conditional nature of the debt utilization. If the Seagen acquisition does not close by a specified date (or if Pfizer decides not to pursue it), a Special Mandatory Redemption will be triggered for most of the notes (excluding the 2033 and 2053 Notes). In such an event, these redeemed notes will be repurchased at 101% of their principal amount plus accrued interest. The proceeds from the 2033 and 2053 Notes, however, would be available for general corporate purposes, potentially including existing debt obligations.
PFIZER INC 8-K Report, Corporate Update (May 15, 2023)
This 8-K filing from Pfizer Inc. (PFE) provides an update on the pending acquisition of Seagen Inc. The key information for investors is that Pfizer and Seagen have submitted their respective notification and report forms under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act. This is a necessary step in the regulatory approval process for the merger. While the filing confirms the HSR submission, it does not offer any new financial data or significant strategic shifts. Investors should note that the closing of the merger remains contingent on several factors, including the expiration or termination of the HSR waiting period and potential approval from the European Commission (EC) if the merger is referred for review. The timing of these regulatory approvals will be a critical determinant of when the Seagen acquisition will be completed and when Pfizer can begin to realize the anticipated benefits of this transaction.
PFIZER INC 8-K Report, Financial Results (May 2, 2023)
Pfizer Inc. (PFE) announced its first-quarter 2023 financial results via a press release filed on May 2, 2023. This 8-K filing primarily serves to furnish the press release detailing these results. Investors should note that the information contained within this press release, while crucial for understanding the company's recent performance, is not considered "filed" under Section 18 of the Exchange Act and thus does not carry the same legal implications as a fully filed report. The core of this filing is the press release itself, which provides the operational and financial data for the first quarter of 2023. While the 8-K itself doesn't delve into the specifics of the results, it directs investors to the furnished press release (Exhibit 99) for detailed information regarding revenue, earnings, and other key financial metrics. Investors seeking to understand Pfizer's performance should refer to this press release for comprehensive insights into the company's financial condition and operational results during the period.
PFIZER INC 8-K Report, Shareholder Vote Results (May 1, 2023)
Pfizer Inc. (PFE) filed a Form 8-K on May 1, 2023, detailing the outcomes of its Annual Meeting of Shareholders held on April 27, 2023. The report indicates strong shareholder support for the election of all director nominees and the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year 2023. Additionally, shareholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers and opted for an annual frequency for future advisory votes on executive compensation. However, the filing also reveals that several shareholder proposals did not receive majority support. These include proposals related to termination pay ratification, adopting an independent board chairman policy, requesting feasibility reports on IP transfer for COVID-19 manufacturers, examining the impact of extended patent exclusivities on product access, and reporting on political contributions congruency. The overwhelming majority of votes against these proposals suggests that the Board's recommendations were largely followed by shareholders.
PFIZER INC 8-K Report, Material Agreement (Mar 13, 2023)
Pfizer Inc. has announced a significant development through an 8-K filing on March 13, 2023, detailing the entry into a Material Definitive Agreement to acquire Seagen Inc. The agreement outlines Pfizer's intent to acquire Seagen for $229.00 per share in cash, representing a substantial cash transaction. This acquisition, structured as a merger where Seagen will become a wholly owned subsidiary of Pfizer, is a strategic move aimed at bolstering Pfizer's oncology portfolio. The acquisition is subject to customary closing conditions, including regulatory approvals (such as HSR and certain non-U.S. antitrust reviews) and the adoption of the merger agreement by Seagen's stockholders. The filing also includes details on termination fees for both parties, with a notable $1.65 billion fee payable by Seagen under specific circumstances (like accepting a superior proposal) and a $2.22 billion fee payable by Pfizer if certain regulatory conditions related to antitrust laws are not met. Accompanying this filing are a joint press release and an investor presentation, providing further context on the strategic rationale and terms of the transaction.
PFIZER INC 8-K Report, Corporate Update (Feb 21, 2023)
Pfizer Inc. (PFE) has officially relocated its corporate headquarters as of February 21, 2023. The new address is 66 Hudson Boulevard East, New York, NY 10001-2192. This relocation signifies a potential strategic move for the company, possibly reflecting changes in operational needs, talent acquisition strategies, or a desire to be in a more centralized or modern business hub. While the physical address change is the primary event disclosed, investors should consider the broader implications of such a move, which can sometimes be associated with significant operational adjustments, lease agreements, and potential impacts on employee logistics. It is important to note that this filing does not disclose any financial performance details or strategic shifts related to the relocation itself. The telephone number for Pfizer remains unchanged, indicating that core communication channels are unaffected. Investors seeking to understand the financial or operational ramifications of this headquarters move should look for further disclosures or interpret it within the context of Pfizer's overall business strategy and ongoing operational updates.
PFIZER INC 8-K Report, Financial Results (Jan 31, 2023)
Pfizer Inc. (PFE) filed an 8-K on January 31, 2023, to announce its financial results for the fourth quarter and full year of 2022. The report primarily serves as a notification that a press release containing these financial details was issued on the same day. Investors should refer to the furnished press release (Exhibit 99) for specific financial performance figures, including revenue, earnings, and any forward-looking guidance. While this 8-K itself does not contain the detailed financial numbers, it signifies the official release of Pfizer's 2022 performance. The filing's purpose is to ensure timely disclosure of material information to the market, making the accompanying press release the critical document for understanding the company's financial health and outlook.
PFIZER INC 8-K Report, Bylaw Amendment (Dec 13, 2022)
Pfizer Inc. (PFE) has filed an 8-K report detailing amendments to its corporate bylaws, effective December 9, 2022. The primary change addresses shareholder proxy solicitations for director nominations, specifically aligning with Rule 14a-19 of the Securities Exchange Act of 1934, commonly known as the "universal proxy rules." These amendments are designed to enhance transparency and compliance in the director nomination and election process, particularly in contested proxy solicitations. For investors, this update signifies a procedural adjustment rather than a change in the company's financial performance or strategic direction. The core implication is that shareholders seeking to nominate directors will need to adhere to stricter disclosure and solicitation requirements, including providing evidence of compliance with the universal proxy rules. This aims to ensure a more standardized and informative voting process for all shareholders, especially in situations involving multiple director candidates.
PFIZER INC 8-K Report, Financial Results (Nov 1, 2022)
Pfizer Inc. (PFE) filed an 8-K on November 1, 2022, to announce its third-quarter 2022 financial results, which were released via a press release on the same date. This filing primarily serves to incorporate by reference the detailed financial performance and operational updates contained within the accompanying press release (Exhibit 99). Investors should refer to the furnished press release for specific details regarding Pfizer's third-quarter performance, including revenue, earnings, and any forward-looking guidance or strategic developments. The 8-K itself does not contain the financial data but directs stakeholders to the primary source document for a comprehensive understanding of the company's recent financial health and operational achievements.
PFIZER INC 8-K Report, Financial Results (Jul 28, 2022)
Pfizer Inc. (PFE) filed an 8-K on July 28, 2022, primarily to furnish a press release announcing its second quarter 2022 financial results. The press release, furnished as Exhibit 99, details the company's performance for the period ending July 27, 2022. Investors should review this press release for specific financial metrics, operational updates, and management's commentary on the quarter's outcomes. While the 8-K itself does not contain the detailed financial figures, it serves as the official notification that these results are available. The furnished press release is the key document for understanding Pfizer's financial condition and results of operations for the second quarter of 2022, including any forward-looking statements or guidance provided by the company. Investors are advised to consult Exhibit 99 directly for comprehensive information.
PFIZER INC 8-K Report, Regulation FD Disclosure (May 10, 2022)
Pfizer Inc. has announced its entry into a Merger Agreement to acquire Biohaven Pharmaceutical Holding Company Ltd. This strategic move, expected to close in Q4 2022, significantly bolsters Pfizer's migraine portfolio by acquiring Biohaven's CGRP (Calcitonin Gene-Related Peptide) programs. The acquisition includes the approved drug rimegepant (NURTEC® ODT) and the Phase 3 drug zavegepant, along with five pre-clinical CGRP assets. The transaction involves a spin-off structure where Biohaven will first distribute certain assets to a new entity, SpinCo, which will then be distributed to Biohaven shareholders. Pfizer will acquire the remaining Biohaven entity and will provide cash payments of $148.50 per Biohaven share, along with 0.5 shares of SpinCo per Biohaven share. Pfizer plans to finance the acquisition with existing cash. This deal is a significant step for Pfizer in expanding its neurological disease offerings, particularly in the lucrative migraine market.
PFIZER INC 8-K Report, Financial Results (May 3, 2022)
Pfizer Inc. (PFE) filed an 8-K on May 3, 2022, to report its first-quarter 2022 financial results. The filing primarily serves to furnish a press release announcing these results, which investors can refer to for detailed operational and financial performance. This report is significant for understanding the company's recent financial health and outlook as presented by management. While the 8-K itself doesn't contain the financial figures, it directs investors to the accompanying press release (Exhibit 99) for the specifics of Q1 2022 performance. Key areas of interest for investors would typically include revenue, earnings per share (EPS), product sales (especially for key drugs like the COVID-19 vaccine and Paxlovid), and any forward-looking guidance provided by the company. Investors should review the furnished press release for these crucial metrics and any commentary on business trends or strategic developments.
PFIZER INC 8-K Report, Shareholder Vote Results (May 2, 2022)
Pfizer Inc. filed an 8-K report on May 2, 2022, detailing the results of its Annual Meeting of Shareholders held on April 28, 2022. The meeting primarily focused on shareholder voting on key corporate matters, including the election of directors, ratification of the independent auditor, and executive compensation. All director nominees presented were overwhelmingly elected. Additionally, shareholders approved the appointment of KPMG LLP as the company's independent registered public accounting firm for the 2022 fiscal year and, on an advisory basis, the compensation of the company's Named Executive Officers. The filing also shows that several shareholder proposals were voted upon and not approved. These proposals covered topics such as amending proxy access, reporting on political expenditures, intellectual property transfer related to COVID-19 manufacturers, board oversight of anti-competitive practices, and public health costs associated with vaccine technology. The strong support for director elections, auditor ratification, and executive compensation indicates shareholder confidence in the current leadership and financial oversight, while the rejection of shareholder proposals suggests a divergence of views on specific governance and operational initiatives.
PFIZER INC 8-K Report, Financial Results (Apr 20, 2022)
This 8-K filing from Pfizer Inc. (PFE), dated April 20, 2022, primarily announces a change in how the company calculates its non-GAAP Adjusted income and Adjusted diluted EPS, effective the first quarter of 2022. Specifically, Pfizer will now include all acquired in-process research and development (IPR&D) costs, including those from collaboration and in-license agreements, and asset acquisitions of IPR&D, in its non-GAAP adjusted results. This change is being made after consultation with the SEC staff. The company anticipates this change will reduce its Adjusted income by approximately $275 million and Adjusted diluted EPS by $0.05 for the first quarter of 2022. Pfizer also stated that it will report IPR&D expenses as a separate line item in its financial statements and will recast prior periods to conform to this new presentation. Full-year financial guidance will also begin to incorporate the impact of acquired IPR&D expenses incurred or signed through a defined date.
PFIZER INC 8-K Report, Executive Changes (Apr 12, 2022)
Pfizer Inc. has announced a significant leadership change with the appointment of David M. Denton as its new Chief Financial Officer (CFO) and Executive Vice President, effective May 2, 2022. Mr. Denton brings a wealth of experience to Pfizer, having previously served as CFO for Lowe's Companies, Inc. and CVS Health, with over 25 years in finance and operations, including extensive experience in the healthcare sector. This appointment follows the previously announced departure of Frank D’Amelio, who will transition from his CFO role after a nearly 15-year tenure and will remain as a special advisor to ensure a smooth handover of responsibilities. The appointment of Mr. Denton is accompanied by a comprehensive compensation package designed to attract and retain top talent. This includes a base salary of $1,250,000 and a target annual cash incentive of $1,250,000. To compensate for potential forfeited benefits from his previous role, Pfizer will provide a one-time cash payment of $5,000,000, an equity grant of restricted stock units (RSUs) valued at $3,250,000, and a credit of $9,750,000 to the Pfizer Supplemental Savings Plan. These arrangements are structured with vesting conditions and clawback provisions to align with Pfizer's interests.
PFIZER INC 8-K Report, Corporate Update (Mar 29, 2022)
This 8-K filing by Pfizer Inc. (PFE) details significant financing activities related to the planned demerger of the GlaxoSmithKline Consumer Healthcare joint venture (CH JVCo). While Pfizer retains a 32% ownership stake in CH JVCo, the report primarily concerns the debt offerings by subsidiaries of CH JVCo, totaling billions of dollars across various currencies (USD, GBP, EUR) and maturities. These offerings are intended to fund a portion of a cash dividend to be distributed to GSK and Pfizer, reflecting their respective ownership interests prior to the demerger. The filing also clarifies the conditions under which these notes would be redeemed and outlines guarantees and indemnification agreements between GSK and Pfizer related to these debt instruments.